https://www.selleckchem.com/products/af353.html
59, 95% confidence interval (CI), 1.17-2.17; HR 1.44, 95% CI, 1.03-2.00; HR 1.52, 95% CI, 1.02-2.25, HR 1.34, 95% CI, 1.04-1.73]. Study heterogeneity was low and not statistically significant under all PD-L1 cutoffs. PD-L1 expression is consistently associated with worse survival, regardless of how it is quantified. In addition to acting as a prognostic biomarker, PD-L1 may also be used in future as a predictive biomarker for patients most likely to benefit from adjuvant immunotherapy. PD-L1 expression is consistently associated with wors